In 2016 Russian specialists from St. Petersburg intend to present the drug for the treatment of cancer. The authorship of the design is owned by biotech corporations "biokad". The drug belongs to the group of chemotherapeutic agents and is a domestic analogue of bevacizumab.
Note that no laboratory in the world, except St. Petersburg, are unable to synthesize the molecule of bevacizumab. Development of Russian pharmacists first in its field. It is assumed that local chemotherapy will have high efficiency and lower price than foreign bevacizumab.
The medicine should appear on sale next year. Experts do not rule out possible difficulties related to the conduct of the last stages of clinical trials and short delay.